The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer : systematic reviews
Black, C. (Corrinda)
De Verteuil, R. (Robyn)
Ayres, J. G.
Bain, L. (Lynda)
Godden, D. J. (David John)
- Publisher: National Coordinating Centre for Health Technology Assessment
Screening for lung cancer has been the subject of\ud debate for the past three decades. This has largely\ud stemmed from the results of chest X-ray screening\ud studies where improvements in survival were\ud obtained but without reductions in disease-specific,\ud or total, mortality. The debate raises two issues:\ud the design of studies to evaluate screening for\ud lung cancer, in particular the choice of\ud comparator; and the potential role of overdiagnosis of well-differentiated, slow-growing\ud tumours that would not have led to symptoms or\ud death in the lifetime of the affected patient.\ud Lung cancer is the leading cause of death from\ud cancer in the UK, killing approximately 34,000\ud people per year. By the time symptoms develop,\ud the tumour is often at an advanced stage and the\ud prognosis is bleak. Treatment at a less advanced\ud stage of disease with surgical resection has been\ud shown to substantially reduce mortality. \ud Screening would be attractive if it could detect\ud presymptomatic lung cancer at a stage when\ud surgical intervention is feasible.
views in local repository
downloads in local repository
The information is available from the following content providers: